IP Library › Granted Patent US 12,201,645
Granted Patent B2
US 12,201,645 · App. 16/696,103 · Granted Jan 21, 2025

Methods of treating myelodysplastic syndrome

Inventors: Jacqueline Cirillo Bussolari (Raritan, NJ); Fei Huang (North Wales, PA); Aleksandra Rizo (Raritan, NJ)
Assignee: Geron Corporation
A61K31/7125A61K31/4439A61K31/706A61P35/00G01N33/573
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,645
App. No.
16/696,103
Granted
Jan 21, 2025
Kind
B2
Abstract

Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA). In some instances, the telomerase inhibitor is imetelstat sodium.

Claims (67)

1. A method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, the method comprising:

measuring human telomerase reverse transcriptase (hTERT) expression level in a biological sample of target cells obtained from the subject after administration a telomerase inhibitor; and

comparing the hTERT expression level in the biological sample to a baseline hTERT expression level prior to administration of the telomerase inhibitor;

wherein a 50% or greater reduction in hTERT expression level in the biological sample after administration of the telomerase inhibitor identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor, and

wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the hTERT expression level measured or assessed is hTERT RNA expression level.

3. The method of claim 1 , wherein the hTERT expression level measured or assessed is hTERT protein expression level.

4. The method of claim 1 , wherein the imetelstat is imetelstat sodium.

5. The method of claim 1 , wherein the MDS is relapsed or refractory MDS and wherein the subject is classified as a low or intermediate-1 IPSS risk MDS subject.

6. The method of claim 1 , wherein the subject is transfusion dependent.

7. The method of claim 1 , wherein the subject is a non-del5q human patient.

8. The method of claim 1 , wherein the subject is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide.

9. The method of claim 1 , wherein the subject has trisomy 8.

10. The method of claim 9 , wherein the subject has trisomy 8 with mosaicism.

11. A method of treating myelodysplastic syndrome (MDS) in a subject, the method comprising:

classifying the subject as having a reduction in human telomerase reverse transcriptase (hTERT) expression level in a biological sample of target cells after administration of the telomerase inhibitor as compared to a baseline expression level prior to administration of the telomerase inhibitor, wherein a 50% or greater reduction in hTERT expression level in the biological sample after administration of the telomerase inhibitor identifies the subject as having an increased likelihood of benefiting from treatment with the telomerase inhibitor; and

administering to the subject an effective amount of a telomerase inhibitor, wherein the administering is effective for treating MDS in the subject, and

wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the hTERT expression level measured or assessed is hTERT RNA expression level.

13. The method of claim 11 , wherein the hTERT expression level measured or assessed is hTERT protein expression level.

14. The method of claim 11 , wherein the imetelstat is imetelstat sodium.

15. The method of claim 11 , wherein the MDS is relapsed or refractory MDS.

16. The method of claim 11 , wherein the MDS is MDS relapsed or refractory to erythropoiesis-stimulating agent (ESA).

17. The method of claim 11 , wherein the subject is classified as a low or intermediate-1 IPSS risk MDS subject.

18. The method of claim 11 , wherein the subject is transfusion dependent.

19. The method of claim 18 , wherein the transfusion dependent subject has a transfusion requirement of about 4 units or more during the 8 weeks prior to the administration of the telomerase inhibitor.

20. The method of claim 11 , wherein the subject is a non-del5q human patient.

21. The method of claim 11 , wherein the subject is naive to treatment with an agent selected from a hypomethylating agent (HMA), lenalidomide, and combination thereof.

22. The method of claim 21 , wherein the subject is naive to treatment with HMA selected from decitabine and azacitidine.

23. The method of claim 21 , wherein the subject is naive to treatment with lenalidomide.

24. The method of claim 11 , wherein the subject has trisomy 8.

25. The method of claim 24 , wherein the subject has trisomy 8 with mosaicism.

26. The method of claim 11 , further comprising altering the dosage of the telomerase inhibitor, the frequency of dosing, or the course of therapy administered to the subject.

27. The method of claim 11 , wherein the telomerase inhibitor is administered for 1, 2, 3, 4, 5, 6, 7, 8 or more than 8 dosage cycles, each cycle comprising:

intravenous administration of about 7-10 mg/kg imetelstat once every four weeks;

intravenous administration of about 7-10 mg/kg imetelstat once weekly for four weeks;

intravenous administration of about 2.5-10 mg/kg imetelstat once every three weeks; or

intravenous administration of about 0.5-9.4 mg/kg imetelstat once every four weeks.

28. The method of claim 27 , wherein each dosage cycle comprises intravenous administration of about 7-10 mg/kg imetelstat once every four weeks.

29. A method of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS), the method comprising:

measuring human telomerase reverse transcriptase (hTERT) expression level in a biological sample of target cells obtained from the subject after administration of a telomerase inhibitor; and

comparing the hTERT expression level in the biological sample to a baseline hTERT expression level prior to administration of the telomerase inhibitor;

wherein a 50% or greater reduction in hTERT expression level in the biological sample after administration of the telomerase inhibitor identifies a subject who has an increased likelihood of benefiting from treatment the telomerase inhibitor, and

wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.

30. The method of claim 29 , wherein the imetelstat is imetelstat sodium.

31. The method of claim 29 , wherein the subject is transfusion dependent.

32. The method of claim 29 , wherein the subject has trisomy 8.

33. The method of claim 32 , wherein the subject has trisomy 8 with mosaicism.

34. A method of identifying and treating a subject with myelodysplastic syndrome (MDS) with a telomerase inhibitor, the method comprising:

diagnosing the subject with trisomy 8, wherein the diagnosis of trisomy 8 in the subject identifies the subject having an increased likelihood of benefitting from treatment with the telomerase inhibitor; and

administering to the subject with trisomy 8 an effective amount of the telomerase inhibitor;

wherein the administering is effective for treating MDS in the subject, and

wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.

35. The method of claim 34 , wherein the imetelstat is imetelstat sodium.

36. The method of claim 34 , wherein the subject is naive to treatment with an agent selected from a hypomethylating agent (HMA), lenalidomide, and combination thereof.

37. The method of claim 34 , wherein the subject is transfusion dependent.

38. A method of treating myelodysplastic syndrome (MDS), the method comprising:

administering to a subject in need thereof an effective amount of a telomerase inhibitor, wherein the subject is diagnosed as having trisomy 8, wherein the diagnosis of trisomy 8 in the subject identifies the subject having an increased likelihood of benefitting from treatment with the telomerase inhibitor, and

wherein the telomerase inhibitor is imetelstat or a pharmaceutically acceptable salt thereof.

39. The method of claim 38 , wherein the imetelstat is imetelstat sodium.

40. The method of claim 38 , wherein the MDS is relapsed or refractory MDS.

41. The method of claim 38 , wherein the MDS is MDS relapsed or refractory to erythropoiesis-stimulating agent (ESA).

42. The method of claim 38 , wherein the subject is classified as a low or intermediate-1 IPSS risk MDS subject.

43. The method of claim 38 , wherein the subject is transfusion dependent.

44. The method of claim 43 , wherein the transfusion dependent subject has a transfusion requirement of about 4 units or more during the 8 weeks prior to the administration of the telomerase inhibitor.

45. The method of claim 38 , wherein the subject is a non-del5q human patient.

46. The method of claim 38 , wherein the subject is naive to treatment with an agent selected from a hypomethylating agent (HMA), lenalidomide, and combination thereof.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Mar 18, 2025
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 070551/0709 →
PATENT SECURITY AGREEMENT Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2021
From: BUSSOLARI, JACQUELINE CIRILLO; HUANG, FEI; RIZO, ALEKSANDRA
To: GERON CORPORATION
Reel/Frame 056219/0142 →
Continuity (4)
Provisional Application 62860557 · Jun 12, 2019
Provisional Application 62811271 · Feb 27, 2019
Provisional Application 62772861 · Nov 29, 2018
Related Publication 20200171072A1 · Jun 4, 2020
References Cited (303)
US 5583016A · Villeponteau et al. · 1996 [cited by applicant]
US 5656638A · Gaeta et al. · 1997 [cited by applicant]
US 5695932A · West et al. · 1997 [cited by applicant]
US 5760062A · Gaeta et al. · 1998 [cited by applicant]
US 5767278A · Gaeta et al. · 1998 [cited by applicant]
US 5770613A · Gaeta et al. · 1998 [cited by applicant]
US 5840490A · Bacchetti et al. · 1998 [cited by applicant]
US 5863936A · Gaeta et al. · 1999 [cited by applicant]
US 5952490A · Hanecak et al. · 1999 [cited by applicant]
US 5958680A · Villeponteau et al. · 1999 [cited by applicant]
US 6261836B1 · Cech et al. · 2001 [cited by applicant]
US 6331399B1 · Monia et al. · 2001 [cited by applicant]
US 6368789B1 · West et al. · 2002 [cited by applicant]
US 6444650B1 · Cech et al. · 2002 [cited by applicant]
US 6548298B2 · Villeponteau et al. · 2003 [cited by applicant]
US 6608036B1 · Gryaznov et al. · 2003 [cited by applicant]
US 7067497B2 · Hanecak et al. · 2006 [cited by applicant]
US 7321029B2 · Gryaznov et al. · 2008 [cited by applicant]
US 7485717B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7494982B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7563618B2 · Gryaznov et al. · 2009 [cited by applicant]
US 7989428B2 · Go et al. · 2011 [cited by applicant]
US 7989603B2 · Gryaznov et al. · 2011 [cited by applicant]
US 7998938B2 · Moore et al. · 2011 [cited by applicant]
US 8153604B2 · Deen et al. · 2012 [cited by applicant]
US 8377644B2 · Gryaznov et al. · 2013 [cited by applicant]
US 8440635B2 · Gryaznov et al. · 2013 [cited by applicant]
US 8906615B2 · Gryaznov et al. · 2014 [cited by applicant]
US 9133233B2 · Gryaznov et al. · 2015 [cited by applicant]
US 9375485B2 · Stuart · 2016 [cited by examiner]
US 9388415B2 · Gryaznov · 2016 [cited by applicant]
US 9404112B2 · Gryaznov · 2016 [cited by applicant]
US 11123359B2 · Tefferi · 2021 [cited by applicant]
US 20050113325A1 · Gryaznov et al. · 2005 [cited by applicant]
US 20050282893A1 · Au et al. · 2005 [cited by applicant]
US 20060009636A1 · Gryaznov et al. · 2006 [cited by applicant]
US 20060166221A1 · Bahou et al. · 2006 [cited by applicant]
US 20070015723A1 · Hanecak et al. · 2007 [cited by applicant]
US 20070224598A1 · Chang · 2007 [cited by applicant]
US 20070270363A1 · Bennett et al. · 2007 [cited by applicant]
US 20090162849A1 · Vainchenker et al. · 2009 [cited by applicant]
US 20090227681A1 · Dimock · 2009 [cited by applicant]
US 20100104586A1 · Tressler et al. · 2010 [cited by applicant]
US 20110263685A1 · Harley et al. · 2011 [cited by applicant]
US 20120032072A1 · Quarmby · 2012 [cited by applicant]
US 20120322072A1 · Nygren · 2012 [cited by applicant]
US 20130253042A1 · Gryaznov et al. · 2013 [cited by applicant]
US 20140155465A1 · Bassett et al. · 2014 [cited by applicant]
US 20140163090A1 · Stuart et al. · 2014 [cited by applicant]
US 20140193518A1 · Sayeski et al. · 2014 [cited by applicant]
US 20140329890A1 · Gryaznov et al. · 2014 [cited by applicant]
US 20150005250A1 · Rollison et al. · 2015 [cited by applicant]
US 20150017119A1 · Fantl et al. · 2015 [cited by applicant]
US 20150299232A1 · Gryaznov et al. · 2015 [cited by applicant]
US 20150342982A1 · Stuart et al. · 2015 [cited by applicant]
US 20160287625A1 · Tefferi · 2016 [cited by applicant]
US 20170051287A1 · Stuart et al. · 2017 [cited by applicant]
US 20180036336A1 · Huang et al. · 2018 [cited by applicant]
CN 101220044 · 2008 [cited by applicant]
JP 2016537423 · 2016 [cited by applicant]
WO 2001018015 · 2001 [cited by applicant]
WO WO20020077184 · 2002 [cited by applicant]
WO WO2004029277 · 2004 [cited by applicant]
WO WO2008054711 · 2004 [cited by applicant]
WO 2005023994 · 2005 [cited by applicant]
WO WO2006113426 · 2006 [cited by applicant]
WO WO2007016354 · 2007 [cited by applicant]
WO WO2014085632 · 2008 [cited by applicant]
WO WO2008112129 · 2008 [cited by applicant]
WO WO2010045245 · 2010 [cited by applicant]
WO WO2011017096 · 2011 [cited by applicant]
WO WO2011098901 · 2011 [cited by applicant]
WO WO2013059738 · 2013 [cited by applicant]
WO 2014088785 · 2014 [cited by applicant]
WO WO2015069758 · 2014 [cited by applicant]
WO WO2014160071 · 2014 [cited by applicant]
WO WO2018026646 · 2018 [cited by applicant]
WO 2019023667 · 2019 [cited by applicant]
Tefferi et al (Blood Cancer Journal (Mar. 2016) 6, e405; doi:10.1038/bcj.2016.13, 2 pages). [cited by examiner]
Mosoyan et al. (Leukemia, 2017, 31:2458-2467). [cited by examiner]
Patnaik et al (Am. J. Hematol. 90(6): 550-559, 2015). [cited by examiner]
Haase et al. (Blood 110(13):4385-4395, 2007). [cited by examiner]
Paulsson et al. (Pathol Biol (Paris) 2007; 55: 37-48). [cited by examiner]
Fragkiadaki et al. (Molecular Medicine Reports, 2022 vol. 25:158, pp. 1-11). [cited by examiner]
Mascarenhas et al. (Abstract 347. Session 634, Presented at American Society of Hematology National Conference 2020). [cited by examiner]
Wayne Kuznar (Jan. 19, 2021, downloaded from https://www.onclive.com/view/imetelstat-disease-modifying-activity-relapsed-refractory-myelofibrosis-shown-effect-telomerase-activity on Nov. 28, 2023). [cited by examiner]
Santini et al. (Blood (2021) 138 (Supplement 1):2598-2600). [cited by examiner]
Fialkow (1981) “Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell” Blood; 58:916-919. [cited by applicant]
European Search Report for EP 13861008.4 dated Aug. 22, 2016. [cited by applicant]
International Search Report for PCT/US2013/070437 dated Jan. 22, 2014. [cited by applicant]
The Merck Manual 18th Edition, Japanese language version, Nikkei Business Publications, Inc., Apr. 25, 2007, p. 1159-1162. [cited by applicant]
Asai, et al., (2003), “A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent”, Cancer Research, vol. 63, pp. 3931-3939. [cited by applicant]
Baerlocher, et al., (2015), “Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia”, The New England Journal of Medicine, vol. 373, pp. 920-928. [cited by applicant]
Fenaux, et al., (2011), “A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q”, Blood, vol. 118, No. 14, pp. … [cited by applicant]
Fenaux, et al., (2013), “How we treat lower-risk myelodysplastic syndromes”, Blood, vol. 121, No. 21, pp. 4280-4286. [cited by applicant]
Greenberg, et al., (2012), “Revised International Prognostic Scoring System for Myelodysplastic Syndromes”, Blood, vol. 120, No. 12, pp. 2454-2465. [cited by applicant]
Gryaznov, (2010), “Oligonucleotide N3′ → P5′ Phosphoramidates and Thio-Phoshoramidates as Potential Therapeutic Agents”, Chem. Biodivers., vol. 7, pp. 477-493. [cited by applicant]
Herbert, et al., (2005), “Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition”, Oncogene, vol. 24, pp. 5262-5268. [cited by applicant]
Palma, et al. (2013), “Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia”, Experimental Hematology, vol. 41, pp. 615-626. [cited by applicant]
Tefferi, et al., (2015), “A Pilot Study of the Telomerase Inhibitor imetelstat for Myelofibrosis”, The New England Journal of Medicine, Vo. 373, pp. 908-919. [cited by applicant]
Vardiman, et al., (2009), “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and Important changes”, Blood, vol. 114, No. 5, pp. 937-951. [cited by applicant]
Adams (1983) “Hindered dialkylamino nucleoside phosphite reagents in the synthesis of two DNA 51-mers” J. Am. Chem. Soc. 105, 661-663. [cited by applicant]
Baerlocher, et al., “Imetelstat rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) who are Refractory or Intolerant to Prior Therapy:Preliminary… [cited by applicant]
Baerlocher, et al., “Imetelstat: A Novel Approach with Robust Hematologic and Molecular Responses in a Phase 2 study in Patients with Essential Thrombocythemia (ET) who are Refractory or Intolerant to Prior Therapy, Hem… [cited by applicant]
Barbui, et al., “Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?”, Blood 114, 759-763, 2009. [cited by applicant]
Barosi, et al., “Response criteria for essential thrombocytemia and polycythemia vera: result of a European LeukemiaNet consensus conference”, Blood, 113(20), 4829-4833, 2009. [cited by applicant]
Baxter et al., “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders”, Lancet 365, 1054-1061, 2005. [cited by applicant]
Beaucage, “Deoxynucleoside phosphoramidites—A new class of key intermediates of deoxypolynucoleotide synthesis”, Tetra. Lett. 22, p. 1859, 1981. [cited by applicant]
Beer, et al., “How I treat essential throbocythemia” Blook 114, 1472-1482, 2011. [cited by applicant]
Belousov, “Sequence-specific targeting and covalent modification of human genomic DNA”, Nucleic Acids Res. 5(25), 3440-3444, 1997. [cited by applicant]
Blackburn, “E. Telomerases”, Annu. Rev. Biochem. 61, pp. 113-129, 1992.F. [cited by applicant]
Blommers, “Effects on the Introduction of L-Nucleotides into DNA Solution Struction of the Heterochiral Duplex d(G-C-G-(L)T-G-C-G).cntdot.d(C-G-C-A-C-G-C) Studied by NMR Spectroscopy”, Biochemistry 33, 7886-7896, 1994. [cited by applicant]
Brassat, et al., “Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells”, Experimental Hematology, 39(1), 66-76, 2011. [cited by applicant]
Brown, “Chemical synthesis and cloning of a tyrosine tRNA gene”, Meth. Enzymol., 68, 109, 1979. [cited by applicant]
Brunold, C., et al., “Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals”, Blood (ASH Annual Meeting A… [cited by applicant]
Carobbio, et al., “Leukocytosis is a risk factor for thromosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status”, Blood 109(6), 2310-2313, 2007. [cited by applicant]
Carruthers, “Chemical Synthesis and Biological Studies on Mutated Gene-control Regions”, Cold Springs Harbor Symp. Quant. Biol. 47, 411-418, 1982. [cited by applicant]
Catenacci, et al., “Myelodysplasic Syndromes: A Comprehensive Review”, Blood Reviews 19, 301-319, 2005. [cited by applicant]
Cazzola, et al., “Ring Sideroblasts and Sideroblastic Anemias”, Haematologica, 96(6), 789-792, 2011. [cited by applicant]
Chen et al., “Secondary structure of vertebrate telomerase RNA”, Cell 100, pp. 503-514, 2000. [cited by applicant]
Della Porta et al., “Myelodysplastic Syndromes with Bone Marrow Fibrosis” Haematologica, vol. 96, No. 2, 180-183, 2011. [cited by applicant]
Drummond et al., “Dysregulated Expression of the Major Telomerase Components in Leukemic Stem Cells Leukemia”, vol. 19, 381-389, 2005. [cited by applicant]
El-Daly, H, et al., , “Selective Cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532”, Blood vol. 105, No. 4, 1742-1749, 2005. [cited by applicant]
El-Kassar, et al., “Clonality Analysis of Hematopoiesis in Essential Thrombocythemia: Advantages of Studying T Lymphocytes and Platelets” Blood 89, 128-134, 1997. [cited by applicant]
Frenkel, “12-dimethylbenz[a]anthracene induces oxidative DNA modification in vivo” Free Radic. Biol. Med., 19373-19380, 1995. [cited by applicant]
Geron Corporation, Geron Corporation Reports Fourth Quarter and Annual 2012 Financial Results, Press Release, 2012. [cited by applicant]
Geron Corporation, Geron discontinues GRN1005 and Restructures to Focus on Imetelstat Development in Hematologic Malignancies and Solid Tumors with Short Telomeres, Press Release, 2012. [cited by applicant]
Geron Corporation, Geron Updates Imetelstat Development Strategy, Including Progress of Investigator-sponsored study in Myelofibrosis, Press Release, 2013. [cited by applicant]
Geron Corporation, U.S. Appl. No. 16/432,727. [cited by applicant]
Geron Corporation, Geron Press Release, Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential Thrombocythemia at the American Society of Hematology Annual Meeting, Press Release [online], Geron C… [cited by applicant]
Gianelli et al., The European Consensus on Grading of Bone Marrow Fibrosis Allows a Better Prognostication of Patients with Primary Myelofibrosis, Modern Pathol., vol. 25, No. 91193-1202, 2012. [cited by applicant]
Gnatenko, et al., “Transcript profiling of human platelets using microarray and serial analysis of gene expression”, Blood 101, 2285-2293, 2003. [cited by applicant]
Graubert, et al., “Recurrent Mutations in the U2AF1 Splicing Factor in Myelodysplastic Syndromes”, Nat Genet., 44(1)53-57, 2012. [cited by applicant]
Gryaznov et al., “Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions Nucl. Acids Res.” 21pp. 5909-5915, 1993. [cited by applicant]
Gryaznov et al., “Oligonucleotide N3′→P5′ phosphoramidates as antisense agents” Nucl. Acids Res. 24(8), pp. 1508-1514, 1996. [cited by applicant]
Gryaznov et al., “Oligonucleotide N3′→P5′ thiophosphoramidate telomerase template antagonists as potential anticancer agents”, Nucleosides, Nucleotides & Nucl. Acids, 22(5-8), pp. 577-581, 2003. [cited by applicant]
Gryaznov et al., “RNA mimetics: oligoribonucleotide N3′-P5′ phosphoramidates” Nucl. Acids Res., 26(18), pp. 4160-4171, 1998. [cited by applicant]
Gryaznov et al., “Synthesis and properties of oligonucleotides containing aminodeoxythymidine units”, Nucl. Acids Res., 20(13), 3403-3491, 1992. [cited by applicant]
Gryaznov, “Oligonucleotide N3′ →P5′ Phosphoramidates and thio-phosphoramidates as Potential Therapeutic Agents, Chemistry and Biology of Artificial Nucleic Acids”, Wiley-VCH, Weinheim, Mar. 2012, ISBN 9783906390673, pp.… [cited by applicant]
Gryaznov et al., “Oligonucleotide N3′→P5′ phosphoramidates as potential therapeutic agents”, Biochem. Biophys. Acta 1489(1), 131-401, 1999. [cited by applicant]
Gryaznov et al., “Telomerase inhibitors—oligonucleotide phosphoramidates as potential therapeutic agents”, Nucleosides, Nucleotides & Nucl. Acids, 20(4-7), 401-410, 2001. [cited by applicant]
Hanahan, et al., “Hallmarks of Cancer: The Next Generation”, Cell, 144646-144674, 2011. [cited by applicant]
Harley et al., Telomerase, Checkpoints and CancerCancer Surv. 29263-29284, 1997. [cited by applicant]
Harley, “Telomere loss: Mitotic clock or genetic time bomb?” Mutation Res., 256pp. 271-282, 1991. [cited by applicant]
Hennessy et al., “New Approaches in the Treatment of Myelofibrosis”, Cancer, vol. 103, No. 132-143, 2004. [cited by applicant]
Hochreiter et al., “Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer”, Clin. Cancer Res., 12(10), pp. 3184-3192, 2006. [cited by applicant]
James, et al., A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera:, Nature, 434, 1144-1148, 2005. [cited by applicant]
Joseph, et al., “The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines”, Cancer Research, 70(22), 9494-9504, 2010. [cited by applicant]
Kakiuchi et al., Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN, Cytologia (Tokyo), vol. 75, No. 2, 177-183, 2010. [cited by applicant]
Kelland “Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics”, Eur. J Cancer, 41971-41979, 2005. [cited by applicant]
Keller et al., “Telomeres and telomerase in chronic myeloid leukemia: impact for pathogenesis disease progression and targeted therapy” Hematological Oncology, vol. 27, No. 3123-3129, 2009. [cited by applicant]
Kim et al., “A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation”, Proc. Natl. Acad. Sci. USA, 98(14), pp. 7982-7987, 2001. [cited by applicant]
Kim et al., “Telomerase Activity Is High In Essential Thrombocythemia and Polycythemia Vera, but Not In Myelofibrosis—a Comprehensive Analysis on Telomerase Activity and Cytogenetics in Myeloproliferative Neoplasm and M… [cited by applicant]
Kim, et al., “Specific association of human telomerase activity with immortal cells and cancer”, Science, 266pp. 2011-2015, 1994. [cited by applicant]
Kralovics, et al., “A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders”, N. Engl. J. Med., 352, 1779-1790, 2005. [cited by applicant]
Kupihar et al., “Synthesis and application of a novel, crystalline phosphoramidite monomer with thiol terminus, suitable for the synthesis of DNA conjugates”, Bioorg. Med. Chem., 9(5)pp., 1241-1247, 2001. [cited by applicant]
Lasho, et al., “SRSF2 Mutations in Primary Myelofibrosis: Significant Clustering with IDH Mutations and Independent Association with Inferior Overall and Leukemia-Free Survival” Blood, 120(20), 4168-4171, 2012. [cited by applicant]
Lebedeva et al., “Antisense oligonucleotides: promise and reality”, Annu. Rev. Pharmacol. Toxicol., 41pp., 403-419, 2001. [cited by applicant]
Lee et al., “Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy”, Ann. Hematol., 82pp., 492-495, 2003. [cited by applicant]
Levine, et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis”, Cancer Cell, 7387-7397, 2005. [cited by applicant]
Ly et al., “Functional characterization of telomerase RNA variants found in patients with hematologic disorders”, Blood, vol. 105, No. 6, 2332-2339, 2005. [cited by applicant]
Macejak et al., “Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo”, J. Virol., 73(9), pp. 7745-7751, 1999. [cited by applicant]
Makishima, et al., “Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis”, Blood, 119(14), 3203-3210, 2012. [cited by applicant]
Maritz et al., “Targeting telomerase in Hematologic malignancy”, Future Oncology, vol. 6, No. 5769-5789, 2010. [cited by applicant]
McCurdy et al., “An Improved Method for the Synthesis of N3′→P5′ Phosphoramidate Oligonucleotides”, Tetrahedron Lett. 38(2), pp. 207-221, 1997. [cited by applicant]
Meggendorfer, et al., “SRSF2 Mutations in 275 Cases with Chronic Myelomonocytic Leukemia (CMML)” Blood, 120(15), 3080-3088, 2012. [cited by applicant]
Mergny et al., “Natural and Phamacological Regulation of Telomerase”, Nucl. Acids Res., vol. 30, No., 4, 839-865, 2002. [cited by applicant]
Mishra et al., “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery”, Biochem. Biophys. Acta, 1264(2), pp. 229-237, 1995. [cited by applicant]
Narang, “Improved phosphotriester method for the synthesis of gene fragments”, Meth. Enzymol., 6890, 1979. [cited by applicant]
Nelson et al., “N3′-P5′ oligodeoxyribonucleotide phosphoramidates: a new method of synthesis based on a phosphoramidate amine-exchange reaction”, J. Org. Chem., 62pp., 7278-7287, 1997. [cited by applicant]
Nimer, “Essential Thrombocythemia: Another “Heterogeneous Disease” Better Understood?”, Blood 93, 415-416, 1999. [cited by applicant]
Pallis et al., “The Telomerase Inhibitor RHPS4 Induces Telomere Shortening, DNA-Damage and Cell Death in AML Cells and Chemosensitises Cells to Daunorubicin”, Blood, 114(22), 2760, 2009. [cited by applicant]
Papaemmanuil, et al., “Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts”, N Engl J Med. 365(15), 1384-1395, 2011. [cited by applicant]
Pascolo, E., et al., “Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate”, J. Biol. Chem., 277(18), pp. 15566-1557, 2002. [cited by applicant]
Pongracz et al., “Oligonucleotide N3′→P5′ thiophosphoramidates: synthesis and properties”, Tetrahedron Lett., 40pp., 7661-7664, 1999. [cited by applicant]
Pongracz et al., “Novel Short Oligonucleotide Conjugates as Inhibitors of Human Telomerase”, Nucleosides, Nucleotides & Nucleic Acids, 22(5-8), 1627-1629, 2003. [cited by applicant]
Pruzan et al., “Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosporamidates”, Nucl. Acids Res., 30(2), pp. 559-568, 2002. [cited by applicant]
Puri et al., “Novel Therapeutics Targeting Telomerase and Telomeres”, J. Cancer Sci. Ther., vol. 5, e127, 2012. [cited by applicant]
Ratain et al., “A phase I trial of GRN163L (GRN), a first-in-class telomere inhibitor, in advanced solid tumors”, J. Clin. Oncol., 26p. 3581, 2008. [cited by applicant]
Roth et al., “Imetelstat (GRN163L) - telomerase-based cancer therapy”, Recent Results in Cancer Research, vol. 18, 4221-4234, 2010. [cited by applicant]
Roth et al., “Shorth Telomeres and High Telomerase Activity in T-cell Prolymphocytic Leukemia” Leukemia, 21, 2456-2462, 2007. [cited by applicant]
Roth et al., “Telomerase is limiting the growth of acute myeloid leukemia cells”, Leukemia, vol. 17, No. 12, 2410-2417, Dec. 2003. [cited by applicant]
Ruden et al., “Novel anticancer therapeutics targeting telomerase”, Cancer Treatment Reviews, vol. 39, 444-456, 2013. [cited by applicant]
Ruella et al., “Telomere length in pH-negative chronic myeloproliferative neoplasms: it is reduced according to JAK2 V617F mutation allele burden and it is not affected by cytoreductive treatment with hydroxyurea”,ASH A… [cited by applicant]
Rump et al., “Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein”, Bioconjugate Chem., 9pp., 341-349, 1998. [cited by applicant]
Shaffer, “Geron Hit Hard by Termination of Phase II Brain Cancer Trial”, Bioworld Today, vol. 23, No. 235, 1, 4, 7, Dec. 5, 2015. [cited by applicant]
Shammas et al., “Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo”, Leukemia, vol. 22, 1410, 2008. [cited by applicant]
Shay et al., “A survey of telomerase activity in human cancer” Eur. J. Cancer, 33pp., 787-791, 1997. [cited by applicant]
Shea-Herbert, et al., “Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death”, Proc. Natl. Acad. Sci. USA, 96(25), pp. 14276-14281, 1999. [cited by applicant]
Shea-Herbert et al., “Lipid modification of GRN163, an N3′-P5′ thio-phosphoramidate oligonucleotide, enhance the potency of telomerase inhibition”, Oncogene, 24pp., 5262-5268, 2005. [cited by applicant]
Shea-Herbert, et al., “Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors”, Oncogene, 21pp., 638-642, 2002. [cited by applicant]
Shea et al., “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates”, Nucl. Acids Res., 18(13), pp. 3777-3783, 1990. [cited by applicant]
Silver, “Myelofibrosis: Thalidomide Finds a New Disease”, Mayo Clin. Proc., vol. 79, No. 7, 857-858, 2004. [cited by applicant]
Spanoudakis et al., “Dynamics of Telomere's Length and Telomerawe Activity in Philadelphia Chromosom Negative Myeloproliferative Neoplasms”, Leukemia Research, vol. 35, Issue 4, 459-464, 2011. [cited by applicant]
Sumi, M, et al., “A G-quadruplex interactive agent, telomestatin (SOT-095) induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia”, International Journal of Oncology, vol. 24,… [cited by applicant]
Tauchi, T., “Activity of a Novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways”, Oncogene 22(34), 5338-5347, 2003. [cited by applicant]
Tetsuzo, T, et al., “Activity of a novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways”, Oncogene, vol. 22, No. (34), 533… [cited by applicant]
Theophile, K, et al., “The Expression Levels of Telomerase Catalytic Subunit hTERT and Oncogenic MYC is Essential Thrombocythemia are Affected by the Molecular Subtype”, Ann Hematol., 87(4), Epub Dec. 15, 2007, 263-268,… [cited by applicant]
Thol, et al., “Prognostic Significance of ASXL1 Mutations in Patients with Myelodysplastic Syndromes”, J. Clin. Oncol., 29(18), 2499-2506, 2011. [cited by applicant]
Thompson et al., A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL 1112), Clinical Cancer Research; 1-7, 2013. [cited by applicant]
Tokcaer-Keskin et al., “The Effect of Telomerase Template Antagonist GRN163L on Bone-marrow-derived Rat Mesenchymal Stem Cells is Reversible and Associated with Altered Expression”, Stem Cell Reviews and Reports, vol. 6… [cited by applicant]
Uhlmann, E., et al., “Antisense oligonucleotides: a new therapeutic principle”, Chem. Rev., 90, pp. 543-584, 1990. [cited by applicant]
US National Institutes of Health, “Imetelstat Sodium in Treating Patients with Primary or Secondary Myelofibrosis” clinicaltrials.gov NCT01731951, 2012. [cited by applicant]
US National Institutes of Health, “Open Label Study to Evaluate the Activity of Imetelstat in Patients with Essential Thrombocythemia or Polycythemia (ET/PV)”, clinicaltrials.gov NCT01243073, 2010. [cited by applicant]
Van Ziffle et al., “Telomere length in subpopulations of human hematopoetic cells”, Stem Cells, 21654-21660, 2003. [cited by applicant]
Wang et al., “Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma” Blood, 103(1), 258-266, 2004. [cited by applicant]
Ward et al., “Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment”, Mol. Pharmacol., 68:3, pp. 779-786, 2005. [cited by applicant]
Wu et al., “Direct activation of TERT transcription by c-MYC”, Nature Genet. 21220-224, 1999. [cited by applicant]
Wu et al., “GRN163L, a Telomerase Inhibitor for Cancer Treatment”, Chinese Journal of New Drugs, vol. 19, No. 2, Fig. 1, 2010. [cited by applicant]
Yasutaka, K, et al., “Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor”, Telincytologia, vol. 75, No. 2, 177-183, 2010. [cited by applicant]
Yoon et al., “Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity”, A… [cited by applicant]
Zeng, Y., et al., “MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms”, Proc. Natl. Acad. Sci. USA, 100(17), pp. 9779-9784, 2003. [cited by applicant]
Ziakas, “Effect of JAK2 V617F on Thrombotic Risk in Patients with Essential Thrombocythemia: Measuring the Uncertain”, Haematologica 93, 1412-1414, 2008. [cited by applicant]
Adema et al., (2013) “What lies beyond del(5q) in myelodysplastic syndrome?” Haematologica, vol. 98, No. 12, pp. 1819-1821. [cited by applicant]
Ades et al., (2014) “Myelodysplastic Syndromes.” Lancet, vol. 383, No. 9936, pp. 2239-2252. [cited by applicant]
Almeida et al., (2017) “Recent Advances in the Treatment of Lower-Risk Non-del(5g) Myelodysplastic Syndromes (MDS).” Leukemia Research, vol. 52, pp. 50-57. [cited by applicant]
Baerlocher et al., (2019) “Imetelstat Inhibits Growth of Megakaryocyte Colony-forming Units From Patients with Essential Thrombocythemia.” Blood Advances, vol. 3, No. 22, pp. 3724-3728. [cited by applicant]
Baerlocher et al., (2015) Supplementary Appendix, New England Journal of Medicine, vol. 373, pp. 920-928. [cited by applicant]
Beier et al., (2015) “Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.” Leukemia Research, vol. 39, pp. 1292-1298. [cited by applicant]
Bièche et al., (2000) “Quantitation of hTERT Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay.” Clin Cancer Res, vol. 6, pp. 452-459. [cited by applicant]
Blasco et al., (1997) “Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA.” Cell, vol. 91, pp. 25-34. [cited by applicant]
Briatore et al., (2009) “Increase of telomerase activity and hTERT expression in myelodysplastic syndromes.” Cancer Biology and Therapy, vol. 8, No. 10, pp. 883-889. [cited by applicant]
Bruedigam et al., (2014) “Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse Following Chemotherapy.” Cell Stem Cell, vol. 15, pp. 775-790. [cited by applicant]
Cervantes, (2014) “How I treat myelofibrosis.” Blood, vol. 124, No. 17, pp. 2635-2642. [cited by applicant]
Crawford et al., (2009) “Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.” Cancer, vol. 95, No. 4, pp. 888-895. [cited by applicant]
Dong et al., (2016) “MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells.” Oncotarget, vol. 7, No. 44, pp. 71904-71914. [cited by applicant]
Ebrahim et al., (2016) “Hematologic malignancies: new strategies to counter the BCL-2 protein.” J. Cancer Res. Clin. Oncol., vol. 142, pp. 2013-2022. [cited by applicant]
European Search Report issued in European Application No. EP16197293.0 dated Apr. 5, 2017. [cited by applicant]
Fenaux et al., (2017) “Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge).” Blood, American Society of Hematolo… [cited by applicant]
Fili et al., (2013) “Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/int-1-risk myelodysplastic syndromes.” Clin Cancer res., vol. 19, N… [cited by applicant]
Fischer et al., (2015) “Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.” Nature Genetics, vol. 47, No. 9., 13 pages. [cited by applicant]
Garcia-Manero et al., (2011) “Hypomethylating agents and other novel strategies in myelodysplastic syndromes.” J. Clin Oncol., vol. 29, No. 5, pp. 516-523. [cited by applicant]
Gissingler et al., (2016) “Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis.” Blood, vol. 128, 1931, 4 pages. [cited by applicant]
Greenberg et al., (1997) “International scoring system for evaluating prognosis in myelodysplastic syndromes.” Blood, vol. 89, No. 6, pp. 2079-2088. [cited by applicant]
Guglielmelli et al., (2014) “The number of prognostically detriment mutations and prognosis in primary myelofibrosis: an international study of 797 patients.” Leukemia, vol. 28, No. 9, pp. 1804-1810. [cited by applicant]
Harley et al. (1990) “Telomeres shorten during ageing of human fibroblasts.” Nature, vol. 345, pp. 458-460. [cited by applicant]
Hellstrom-Lindberg et al., (2003) “A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.” B… [cited by applicant]
Hu, et al., (2019) Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells. Blood, vol. 134, No. 1, 963, 2 pages. [cited by applicant]
Hultdin, M, et al. (1998) Telomere analysis by fluorescence in situ hybridization and flow cytometry Nucl. Acids Res., vol. 26, No. 16, pp. 3651-3656. [cited by applicant]
International Search Report issued in PCT/US2017/044348 mailed Oct. 10, 2017. [cited by applicant]
International Search Report issued in PCT/US2018/044225 mailed Oct. 10, 2018. [cited by applicant]
Janssen Research & Development L Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) ClinicalTrials.gov J… [cited by applicant]
Jin et al., (2005) “Down Regulation of hTERT Is an Important Mechanism in Apoptosis of MUTZ-1 Cells Induced by As203” Blood, American Society of Hematology, vol. 106, No. 11, 4910. [cited by applicant]
Kelaidi et al. (2013) “Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.” Leukemia, vol. 27, No. 6, pp. 1283-1290. [cited by applicant]
Kuykendall et al. (2018) “Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.” Annals of Hematology, vol. 97, pp. 435-441. [cited by applicant]
Langabeer et al., (2016) “Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.” JAK-STAT, vol. 5, pp. e1248011-1-e1248011-5. [cited by applicant]
Lange et al., (2010) “Telomere Shortening and Chromosomal Instability in Myelodysplastic Syndromes.” Genes, Chromosomes & Cancer, vol. 49, pp. 260-269. [cited by applicant]
Leibundgut et al., (2015) “Dynamics of Mutations in Patients with ET Treated with Imetelstat.” Blood, vol. 126, No. 23, 57, 3 pages. [cited by applicant]
Loiseau et al., (2015) “New therapeutic approaches in myelodysplastic syndromes: hypomethylating agents and lenalidomide.” Exp Hematol., vol. 43, No. 8, pp. 661-672. [cited by applicant]
Malcovati et al., (2006) “Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.” Haematologica, vol. 91, No. 12, pp. 1588-1590. [cited by applicant]
Malcovati et al., (2005) “Prognostic factors and life expectancy in myelodysplastic sydromes classified according to WHO criteria: a basis for clinical decision making.” J Clin. Oncol., vol. 23, pp. 7594-7603. [cited by applicant]
Marty et al., (2016) “Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.” Blood, vol. 127, No. 10, pp. 1317-1324. [cited by applicant]
Mascarenhas et al., (2018) “Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: results of a phase 2 ra… [cited by applicant]
McNamara et al., (2019) EHA; Amsterdam, the Netherlands; Jun. 13, 2019. #PS1460. [cited by applicant]
Mesa et al., (2016) “Individualizing Care for Patients with Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.” Am Soc Clin Oncol Educ Book, vol. 35, pp. 324-335. [cited by applicant]
Mudireddy et al., (2018) “Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons.” Bri J. Haematol., vol. 182, pp. 594-597. [cited by applicant]
Newberry et al., (2017) “Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.” Blood, vol. 130, No. 9, pp. 1125-1131. [cited by applicant]
Oliva et al., (2013) “Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.” Ann Hematol., vol. 92, No. 1, pp. 25-32. [cited by applicant]
Pardanani et al., (2014) “Definition and management of ruxolitinib treatment failure in myelofibrosis.” Blood Cancer Journal, vol. 4, e268, 7 pages. [cited by applicant]
Park et al., (2017) “Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents.” J Clin Oncol., vol. 35, No. 14, pp. 1591-1597. [cited by applicant]
Patnaik et al., (2015) “CME Information: Refractory anemia with ring sideroblasts and RARS with Thrombocytosis.” Am. J. Hematol., vo. 90, No. 6, pp. 550-559. [cited by applicant]
Patnaik et al., (2017) “Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.” American Journal of Hematology, vol. 92, No.… [cited by applicant]
Prebet et al. (2017) “Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.” Oncotarget, vol. 8, No. 23, pp. 37866-37874. [cited by applicant]
Romero, (2015) “Haematological Cancer—Promising Results of BCL2 Inhibition.” Nature Reviews Clinical Oncology, vol. 12, No. 9, 504, 1 page. [cited by applicant]
Ropio et al., (2016) “Telomerase Activation in Hematological Malignancies.” Genes, vol. 7, No. 9, 13 pages. [cited by applicant]
Rufer et al., (1998) “Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry.” Nature Biotechnology, vol. 16, pp. 743-747. [cited by applicant]
Rumi et al., (2014) “Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.” Blood, vol. 124, No. 7, pp. 1062-1069. [cited by applicant]
Rusbuldt et al., (2016) “Abstract 2731: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines.” Cancer Research, American A… [cited by applicant]
Schain et al., (2019) “Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.” Eur J Haematol., vol. 103, pp. 614-619. [cited by applicant]
Shammo et al., (2016) “Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.” Hematology, Am Soc Hematol Educ Program, vol. 2016, No. 1, pp. 552-560. [cited by applicant]
Shreenivas et al., (2018) Emerging drugs for the treatment of Myelofibrosis. Expert Opinion on Emerging Drugs, vol. 23, No. 1, pp. 37-49. [cited by applicant]
Sochacki et al., (2016) “Therapeutic approaches in myelofibrosis and myelodysplastic/myelolproliferative overlap syndromes.” Onco. Targets Ther., vol. 9, pp. 2273-2286. [cited by applicant]
Sole et al., (2005) “Identification of novel cytogenic makers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.” Haematologica, vol. 90, No. 9, pp. 1168-1178. [cited by applicant]
Spiegel et al., (2017) “Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.” Blood Adv., vol. 1, No. 20, pp. 1729-1738. [cited by applicant]
Steensma, (2015) “Myelodysplastic syndromes: diagnosis and treatment.” Mayo Clinic Proc., vol. 90, No. 7, pp. 969-983. [cited by applicant]
Tefferi et al., (2013) “Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions in Myelofibrosis and Reversal of Bone Marrow Fibrosis.” Blood, retrieved from the internet: URL:http://www.bloodjo… [cited by applicant]
Tefferi et al., (2014) “Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.” Blood, vol. 124, No. 16, pp. 2507-2513. [cited by applicant]
Tefferi et al., (2016) “The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.” Journ… [cited by applicant]
Terrin et al., (2007) “Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.” Leukemia, vol. 21, pp… [cited by applicant]
Thépot et al., (2016) “A randomized phase II trial of azacitidine +/- epetin -? in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.” Haematologica, vol. 101, No. 8, pp. 918-925. [cited by applicant]
Tobiasson et al., (2014) “Limited clinical efficacy of azacitidine in tranfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.” Blood Cancer J., vol. 4, e1… [cited by applicant]
UNC School of Medicine, History-Taking and Physical Examination, Medicine Clerkship (May 29, 2010), 3 pages, retrieved from https://www.med.unc.edu/medclerk/resources/cdim-sgim-guide/history-taking-and-physical-examinat… [cited by applicant]
Vannucchi et al., (2013) “Mutations and prognosis in primary myelofibrosis.” Leukemia, vol. 27, pp. 1861-1869. [cited by applicant]
Vasko et al., (2017) “Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.” Int J Mol Sci., vol. 18, No. 11., 14 pages. [cited by applicant]
Wang et al., (2014) “Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.” Blood, vol. 123, No. 17, pp. 2645-2651. [cited by applicant]
Wang et al., (2018) “Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.” Blood Adv., vol. 2, No. 18, pp. 2378-2388. [cited by applicant]
Zijlmans et al., (1997) “Telomeres in the mouse have large inter-chromosomal variations in the No. of T2AG3 repeats.” Proc. Natl. Acad. Sci. USA, vol. 94, pp. 7423-7428. [cited by applicant]
Anonymous, (2016) “Abstract 2731: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines | Cancer Research | American Associ… [cited by applicant]
Drevon et al., (2018) “Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myelodysplasies”, British Journ… [cited by applicant]
Jafri et al., (2016) “Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies”, Genome Medicine, 8(69):1-18. [cited by applicant]
Kishtagari et al., (2017) “Biological and clinical implications of telomere dysfunction in myeloid malignancies”, Ther Adv Hematol, 8(11):317-326. [cited by applicant]
Patel et al., (2015) “Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib”, Blood, 126(6):790-797. [cited by applicant]
Tefferi et al., (2016) “Telomerase Inhibitor Imetelstat Therapy in Refractor Anemia with Ring Sideroblasts with or without Thombocytosis”, Blood Cancer Journal, 6(3):1-2. [cited by applicant]
Clinical Trials (2015) “Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)”, Geron Corporation, 20 pages, NCT… [cited by applicant]
Paulsson and Johansson, (2006) “Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes”, Science Direct, 55:37-48. [cited by applicant]
Janssen Research & Development (2016) “Study to Evaluate Imetelstat (JNJ-63935937) in Subjects with International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)”, ClinicalTria… [cited by applicant]
Palandri et al., (2020) “Life After Ruxolitinib: Reasons for Discontinuation, Impact of Disease Phase, and Outcomes in 218 Patients with Myelofibrosis” Cancer, 126(6):1243-1252. [cited by applicant]
Santini “Treatment of low-risk myelodysplastic syndromes”, Hematology Am Soc Hematol Educ Program, 1:462-469. [cited by applicant]
Smith, (2010) “The clinical and economic burden of anemia.” Am J Manag Care, 16(3):S59-S66. [cited by applicant]
Tefferi et al., (2015) “Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis”, Clinical Trial, 4 pages. [cited by applicant]
Huang, (2018) “New drug research and development”, Journal of International Pharmaceutical Research, 45(1):77. [cited by applicant]
The Merck Manual, (2018) 18th Edition, pp. 1098-1105. [cited by applicant]
Tefferi and Vardiman (2008) “Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms” Leukemia, 22:14-22. [cited by applicant]